Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Takeda Gets Japan Approval for Low-Dose Form of Ninlaro
Takeda Pharmaceutical said on August 16 that it has earned Japanese regulatory approval for an additional 0.5 mg capsule version of its multiple myeloma (MM) drug Ninlaro (ixazomib). The new version, which comes on top of the existing 2.3 mg,…
To read the full story
Related Article
- Takeda’s Fruzaqla Now Available in Japan, AbbVie’s Skyrizi Adds New Version
November 25, 2024
- Takeda Files Low-Dose Form of Ninlaro in Japan
September 25, 2023
BUSINESS
- Leqembi Global Sales Hit 61.8 Billion Yen in April-December: Eisai
February 9, 2026
- Marubeni Rolls Out Antibiotic Xenleta in China
February 9, 2026
- HLC, Mochida Set to Launch Japan PIII Trial of Umbilical Cord-Derived MSC
February 9, 2026
- Japan Ethical Drug Sales Up 3.2% in December: Crecon
February 9, 2026
- Lilly Discloses Japan Filing for Orforglipron, Starting with Obesity
February 6, 2026
Japan’s Biological Raw Material Rules Enter Major Revision; Clarity on Benefits and Safety Holds Key
Japan is poised to make the most sweeping revision in eight years to the Standards for Biological Raw Materials —…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…